Morgan Stanley Forecasts Strong Price Appreciation for Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Morgan Stanley raised its price target on Disc Medicine to $104 from $92 and maintained an Overweight rating, implying 33.84% upside from the prior close.
  • Analyst sentiment is broadly positive: 12 analysts rate the stock Buy, one Hold, and one Sell. The consensus rating is Moderate Buy, with a $125.27 average price target.
  • Disc Medicine reported quarterly EPS of -$1.53, beating analysts’ estimate of -$1.63 by $0.10. Company insiders sold a combined 150,277 shares worth about $11.9 million over the past 90 days.
  • Five stocks to consider instead of Disc Medicine.

Disc Medicine (NASDAQ:IRON - Get Free Report) had its price objective hoisted by analysts at Morgan Stanley from $92.00 to $104.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. Morgan Stanley's target price indicates a potential upside of 33.84% from the company's previous close.

IRON has been the subject of several other research reports. BMO Capital Markets raised their price target on Disc Medicine from $100.00 to $120.00 and gave the company an "outperform" rating in a report on Monday, October 19th. Guggenheim began coverage on shares of Disc Medicine in a report on Monday, November 9th. They issued a "buy" rating and a $132.00 price objective on the stock. Truist Financial increased their price objective on shares of Disc Medicine from $83.00 to $115.00 and gave the company a "buy" rating in a research report on Monday, October 19th. Cantor Fitzgerald raised their target price on shares of Disc Medicine from $125.00 to $170.00 and gave the stock an "overweight" rating in a research note on Monday, October 19th. Finally, Wells Fargo & Company raised their target price on shares of Disc Medicine from $86.00 to $124.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 20th. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $125.27.

Read Our Latest Stock Analysis on Disc Medicine

Disc Medicine Stock Performance

NASDAQ IRON traded up $1.14 during trading on Wednesday, reaching $77.71. 75,796 shares of the company's stock were exchanged, compared to its average volume of 676,511. The company has a debt-to-equity ratio of 0.10, a current ratio of 20.30 and a quick ratio of 20.30. The business has a 50 day moving average price of $71.54 and a 200-day moving average price of $71.04. The stock has a market capitalization of $3.54 billion, a P/E ratio of -12.18 and a beta of 0.96. Disc Medicine has a fifty-two week low of $40.00 and a fifty-two week high of $99.50.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($1.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.63) by $0.10. Sell-side analysts forecast that Disc Medicine will post -6.20 earnings per share for the current fiscal year.

Insider Activity at Disc Medicine

In other Disc Medicine news, COO Jonathan Yu sold 8,796 shares of the company's stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $83.12, for a total value of $731,123.52. Following the transaction, the chief operating officer directly owned 54,324 shares of the company's stock, valued at $4,515,410.88. This represents a 13.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider William Savage sold 16,035 shares of the stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $85.09, for a total value of $1,364,418.15. Following the transaction, the insider owned 63,445 shares in the company, valued at $5,398,535.05. The trade was a 20.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 150,277 shares of company stock worth $11,877,059 in the last ninety days. 3.76% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in IRON. State of Wyoming acquired a new stake in Disc Medicine during the second quarter worth about $25,000. Allworth Financial LP bought a new position in Disc Medicine in the 2nd quarter valued at about $46,000. Sterling Capital Management LLC raised its position in shares of Disc Medicine by 842.4% in the 3rd quarter. Sterling Capital Management LLC now owns 933 shares of the company's stock valued at $61,000 after buying an additional 834 shares in the last quarter. Nykredit A S acquired a new position in shares of Disc Medicine in the 2nd quarter valued at approximately $103,000. Finally, Pinnacle Wealth Planning Services Inc. acquired a new position in shares of Disc Medicine in the 3rd quarter valued at approximately $119,000. 83.70% of the stock is owned by institutional investors.

About Disc Medicine

(Get Free Report)

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function. The company's development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.

Further Reading

Analyst Recommendations for Disc Medicine (NASDAQ:IRON)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Disc Medicine Right Now?

Before you consider Disc Medicine, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.

While Disc Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines